Loading
A phase 2 trial in triple-negative breast cancer, run by Universitas Indonesia, now recruiting.
The Role of Simvastatin in The Epithelial-Mesenchymal Transition Process of Breast Cancer is a phase 2, randomised interventional study registered as NCT05550415 by Universitas Indonesia, with a registry enrolment figure of 26 participants, started 2022-08-19 and due to reach its primary completion in 2026-11. Interventions recorded: Simvastatin 40mg; Placebo. Conditions listed: Triple Negative Breast Cancer; Chemotherapy Effect; Simvastatin Adverse Reaction. Triple-negative eligibility wording from the registry: "Female patients with advanced breast cancer (locally advanced and distantly advanced) with triple-negative molecular type confirmed by biopsy and immunohistochemical examination". Sites: Indonesia. No results are recorded here; the registry entry is the source.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.